For U.S. Investors:
Westwicke
John Woolford Nachricht senden
+1 443 213-0506
Media Contact Jasmina Alatovic
Director Global External Communications Nachricht senden
+49 89 62 81 75 46
Investors & Media
Welcome to our investor page
We aspire to individualize cancer medicine
BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.
Press Releases
15 January 2021
Statement on European Upscaling as well as Impact on Deliveries
11 January 2021
Statement on Voluntary COVID-19 Vaccination for BioNTech Employees and Supplier..
8 January 2021
Statement regarding European Commission’s Proposal to Purchase Additional Doses..